AtriCure (ATRC) and Its Competitors Financial Analysis

AtriCure (NASDAQ:ATRC – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare AtriCure to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations.

Profitability

This table compares AtriCure and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AtriCure 2.52% 4.01% 3.03%
AtriCure Competitors -190.60% -186.87% -21.75%

Institutional and Insider Ownership

99.1% of AtriCure shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for AtriCure and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AtriCure 1 4 6 1 2.58
AtriCure Competitors 4322 10606 18416 841 2.46

AtriCure currently has a consensus target price of $62.30, suggesting a potential upside of 12.35%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 26.36%. Given AtriCure’s rivals higher probable upside, analysts plainly believe AtriCure has less favorable growth aspects than its rivals.

Risk & Volatility

AtriCure has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, AtriCure’s rivals have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.

Valuation and Earnings

This table compares AtriCure and its rivals revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AtriCure $534.53 million -$11.45 million 184.83
AtriCure Competitors $1.89 billion $135.83 million 5.74

AtriCure’s rivals have higher revenue and earnings than AtriCure. AtriCure is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

AtriCure beats its rivals on 7 of the 13 factors compared.

AtriCure Company Profile

(Get Free Report)

AtriCure, Inc. is a medical technology company that develops and sells products for the treatment of atrial fibrillation and other conditions addressed through cardiac surgery. Its technologies are used by surgeons and other medical professionals in hospital settings. The company’s products include surgical ablation systems designed to treat irregular heart rhythms and devices for managing the left atrial appendage, a small pouch in the heart associated with stroke risk in some patients with atrial fibrillation.

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.